News briefs from Genzyme, Sagent, Orchid and Kyowa Hakko

14 November 2012

French drug major Sanofi’s (Euronext: SAN) subsidiary Genzyme, which has had supply problems for several of its leading products in recent years, announced that due to the continued progress in its manufacturing operations this year, its supply of Thyrogen (thyrotropin alfa for injection) has been fully restored. As a result, beginning in November, Genzyme is able to supply all patient demand globally.

“We are grateful to the thyroid cancer treatment community for its ongoing patience and partnership,” said Genzyme’s vice president and general manager of endocrinology, Alicia Secor, adding: “Genzyme continues to invest in our manufacturing capabilities and we are dedicated to delivering high quality product and continuous supply of Thyrogen for the long term.”

Sagent debuts generic Diamox

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK